Coronaviruses (CoVs) typically affect the respiratorytract of mammals, including humans, and lead to mild to severe respiratory tract infections1. In the past two decades, two highly pathogenic human CoVs (HCoVs).

Descargar PDF

La Hidroxicloroquina es un medicamento inmunomodulador utilizado por 60 años para el tratamiento de la malaria y enfermedades autoinmunes tales como lupus eritematoso sistémico y artritis inflamatoria.

Descargar PDF

Lopinavir/ritonavir es una combinación fija de antivirales ampliamente utilizada para tratar la infección por VIH. En el marco de la pandemia por COVID-19 en 2019/2020, se ha sugerido que puede constituir un tratamiento para esta enfermedad.

Descargar PDF

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Descargar PDF

Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.

Descargar PDF

A novel coronavirus disease (COVID-19), caused by infection with SARS-CoV-2, has swept across 31 provinces in China and over 40 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is highly likely to be due to uncontrolled cytokine release.

Descargar PDF

Respiratory viral infections are associated with the majority of asthma exacerbations (,80%) in both adults [1, 2] and children [3, 4]. Asthma exacerbations are the major cause of morbidity, mortality and healthcare costs in asthma [5].

Descargar PDF

A novel infectious disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was detected in Wuhan, China, in December 2019. The disease (COVID-19) spread rapidly, reaching epidemic proportions in China, and has been found in 27 other countries.

Descargar PDF